We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

APH Alliance Pharma Plc

0.70 (1.87%)
Last Updated: 15:03:41
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma Plc LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.70 1.87% 38.10 38.05 38.40 38.40 37.40 37.85 778,794 15:03:41
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 167.42M 936k 0.0017 223.53 205.26M

Alliance Pharma Share Discussion Threads

Showing 2326 to 2349 of 2800 messages
Chat Pages: Latest  100  99  98  97  96  95  94  93  92  91  90  89  Older
2vdm; reported buy and sell numbers are notoriously unreliable and price is more influenced by forward buy/sell orders than transactions already completed.
Please can someone explain to me how there have been apparently 34K buys v 81K sells today, yet the share price has gone up, presumably on anticipation of the results. I'm a LTH her and have been for 10 years
Not long to go for results for year ended 31/12/21 due next Tuesday 22 March.
APH could hardly be unaware of the price rigging taking place, but not sure whether there would be a duty to report
winnings1; no, that is not the question. Many similar arrangements occur across the industry for a variety of reasons. The question is whether APH made the arrangement with knowledge (either explicit or reasonably anticipated) of the activity of the distributor and benefitted from that activity. APH have been clear that they received no financial benefit from the pricing so only the former applies. This investigation falls under the cartel/anti-competitive behaviour function of the CMA and requires that APH be a participant in the behaviour. The only way I can see this being possible is if the CMA claim that APH entered the distribution agreement knowing of the pricing activity and were able to extract some benefit up front as a consequence (given that APH have made it clear they did not receive subsequent benefit). I can find no reference suggesting this is the claim of the CMA.
The question one has to ask is why did APH part with a niche medicine whilst specializing in niche medicines themselve?
winnings; the investigation took 3 elapsed years but was put on hold at the start of the pandemic as priorities were redrawn, so they were working on it for much less time. However that is never the issue in regulatory matters. The L&G case I referenced took multi years but was utterly compromised by the incompetence of the regulators and their political agenda handed down by their government masters. I have unfortunate experience dealing with regulators (the FSA), having had to deal with the director and staff responsible for overseeing the insurer of which I was a director. The FSA manager in charge came from a mortgage background and was so ignorant of insurance that I even had to explain how retail insurance policies were moved from broker to insurer, something so basic a trainee would have known. Most regulator staff are either company rejects or unable to get a job with a company and end up at the regulator because they pay peanuts and have to accept second rate staff. They get away with it because few companies are willing to challenge them. Dave Prosser did at L&G because he was approaching retirement and had had enough. I hope Alliance have the same approach.
Does not look like the Investigation was a rushed affair (took some 3 years). I fear the planned appeal may fail and add to the costs.
wba. Agree with everything that you say, particularly about the FSA. This is a well managed company imo and I will continue to add on any dips. I'll look fwd to the appeal. APH have enough to pay for the current fine, but anyway feel that they are on solid ground to launch the appeal.
Interesting news today regarding the regulatory fine. It seems that the regulator is seeking to make examples of anyone and everyone even peripherally linked to the case in question. The last time I recall such overreach was the action of the FSA attempting to fine L&G millions for misselling, circa 2005. Their then CEO (Dave Prosser) took the regulator to court and eviscerated them, winning on every count. I would urge Alliance to do the same in this case. Regulators who ignore the facts for political purposes need to be thoroughly cleansed by judges who are not beholden to politicians.

I will continue to hold APH as I have since buying in the low 40s. Their business model reminds me of an over the counter Galen - who made me good money many years ago. But I would urge them to exit the regulated prescription drugs sector. No need to have that complication for what is a small part of the business.

......Beximco Pharmaceuticals Limited BXP.L ("Beximco Pharma",or "the Company"), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces the launch of the world's first generic version of Pfizer's COVID-19 treatment Paxlovid (nirmatrelvir and ritonavir tablets, co-packaged for oral use) which was granted emergency use authorization (EUA) by the US FDA on 22 December 2021. Directorate General of Drug Administration (DGDA), Bangladesh, has today granted EUA for the oral antiviral drug to treat mild-to-moderate COVID-19 in adults and children of 12 years and above. This novel antiviral pill showed almost 90% efficacy in preventing hospitali z ations and deaths in high-risk patients, and recent data from Pfizer suggests the drug retains its effectiveness against the fast-spreading Omicron variant of the coronavirus. Beximco Pharma will market this product under the brand name Bexovid, initially in Bangladesh.
Seems to be quietly rising. Now at an all-time high and no sell off after interim dividend qualifying date of 24 Dec.
From WealthOracleAM...

The company we cover today is a very particular business, as it brings expertise to the marketing and regulatory management of products, ensuring it reaches a wide range of people. Alliance is a UK-based specialty pharmaceutical company. They are neither a manufacturer, nor a proper pharmaceuticals developer. This allows them to run an asset-light business (without all of the warehousing and logistics) and keep their focus on the areas of the business where they are experts. A simpler way to describe them would be a retailer for healthcare products. Acquisitions are a rare sight, with one done last year (Biogix) and the previous in 2012, resulting in a low goodwill figure.
Fundamentals look healthy. Revenue CAGR is currently at 21.8%. The one-off drop in EPS from last year is mainly due to non-cash impairment and amortisation charges and the acquisition costs relating to Biogix transaction. This also pushed the ROCE down to 3.41%, but the ratio is rising by a CAGR of 7.99%. Free cash flow was strong supported by favourable movements in working capital and the total dividend was significantly ahead of 2019.

Tipped as a hold in IC this week FWIW.
wad collector
This BB is humming with excitement ever since I acquired some in March. Usually shares drop when I buy them and the BB gets busy. I like this. Though won't buy much with the dividend.

Interim results for the six months ended 30 June 2021

Strong growth from Consumer Healthcare brands and integration of Amberen complete

Full year outlook in line with market expectations

Alliance Pharma plc (AIM: APH), the international healthcare group, announces its interim results for the six months ended 30 June 2021 (the "Period").


-- The Group traded strongly in the Period with an excellent performance from Kelo-cote(TM), an uplift in revenue from Prescription Medicines and a significant contribution from recently acquired Amberen(TM)

-- See-through revenue in total up 24% (+28% on a constant currency basis ("CCY")) to GBP80.9m; like-for-like ("LFL") see-through revenue, which excludes Amberen, up 9% (+12% CCY); statutory revenue up 27% to GBP78.6m (H1 2020 GBP61.7m)

o Strong performance from Consumer Healthcare brands, with see-through revenue up 30% overall (+35% CCY)

-- Kelo-cote revenue up 54% (+62% CCY)

-- LFL Consumer Healthcare revenue up 8% (+12% CCY)

o Prescription Medicines revenue up 12% (+12% CCY)

-- Underlying gross margin up 4.7 % to 63.8% of see-through revenue (H1 2020: 59.1%), reflecting favourable changes in product mix; statutory gross margin up 3.1% to 65.6% (H1 2020: 62.5%)

-- Underlying profit before tax up 24% to GBP20.1m (H1 2020: GBP16.3m); reported profit before tax GBP16.5m (H1 2020: GBP0.6m)

-- Free cash flow GBP6.5m (H1 2020: GBP10.5m), reflecting the expected reversal of favourable working capital movements in Q4 2020 and the timing of sales within the Period

-- Leverage reduced to 2.21 times from 2.43 times at December 2020 and expected to fall below 2.0 times by the end of the year

-- Amberen integration complete and trading in line with management expectations
-- Interim dividend payment of 0.563p, up 5% (interim dividend 2020: 0.536p)

wad collector
Alliance Pharma Rated New Outperform at RBC; PT 106 pence
Decent results and outlook, and good use of non-cash impairments.
The recorded webcast will also be made available at the investor section of Alliance's website, hxxps://
Looking forward to seeing the results for the 12 months ended 31 December 2020 due out next Tuesday.
RNSthis a.m.:
Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the 12 months ended 31 December 2020 on Tuesday 23 March 2021.

A conference call for analysts will be held at 10.30am on 23 March 2021; analysts who require dial-in details, please contact Buchanan at

A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 23 March 2021 at this link:


The recorded webcast will also be made available at the investor section of Alliance's website, hxxps://

For more information, please contact Buchanan on 020 7466 5000 or email

Hi all,

My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast a few days ago and part of our discussion includes APH and some others with a similar business model. We also chatted about loads of other Stocks and Ideas for research and a fair bit of educational stuff with regards to Investing and Portfolio Management.

Anyway, if you use Youtube, Apple, Audioboom, Overcast or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 39) and you can find it on Soundcloud at the link below.

I hope you enjoy it and find it useful, we try to keep them light and they are totally unscripted, not like all the stuffy financial fodder you are probably more used to !!

Happy New Lockdown !! WD

Has anyone here had a look at Beximco Pharmaceuticals (BXP) This company has been appointed to be the sole distributor of the Oxford vaccine for the whole of Bangladesh. The share price has risen significantly off late, but more to come IMHO.
Cheers. But as always do your own research. ws

2vdm; I wish I could deny it after last night. Strange day yesterday - excellent performance across investments followed by the biggest shambles I recall on a football field.
wba1 (please tell me it stands for West Bromwich Albion?). I agree. Immediately profit and cash enhancing with still more money available for a smaller acquisition(s) if a suitable opportunity arises, although I'd prefer to see the Biogenix acquisition settled in and reducing debt overall.
Chat Pages: Latest  100  99  98  97  96  95  94  93  92  91  90  89  Older

Your Recent History

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |